Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

Texas Instruments stock slips as chip ETF firms; investors eye Jan. 27 earnings amid Fed jitters

New York, Jan 12, 2026, 15:11 EST — Regular session.

  • Shares of Texas Instruments slipped roughly 0.2% in afternoon trading.
  • Chip stocks mostly gained, but TXN trailed the pack.
  • Investors are eyeing TI’s Jan. 27 earnings for signs on industrial and auto demand.

Texas Instruments shares slipped slightly on Monday afternoon, lagging behind the steadier semiconductor sector. The stock dipped roughly 0.2% to $189.85.

The split matters since Texas Instruments serves as a bellwether for analog chips — those crucial components inside factory equipment, cars, and common electronics. With its next update looming, positioning is already shifting.

Macro noise isn’t doing any favors. A Justice Department probe touching Federal Reserve Chair Jerome Powell, plus the political fallout, has stirred up fresh doubts over Fed independence, rattling both rates and currency markets. Reuters

Markets have shifted into jittery, uneven moves instead of clear trends. “Gold has strengthened, equities have wobbled, and the yield curve has steepened a little,” noted Damien Boey, portfolio manager at Wilson Asset Management. Reuters

Texas Instruments wasn’t the only one to stall, yet it stood apart from the broader trend: the iShares Semiconductor ETF gained around 0.7%, and Nvidia’s stock climbed about 1% during that period.

A few investors are mainly focused on avoiding missteps ahead of a headline-heavy week. “We need to see some type of action before the market will actually react to it in a meaningful way,” said Jordan Rizzuto, chief investment officer at GammaRoad Capital Partners. Reuters

Texas Instruments is gearing up for its next major event: the Q4 and full-year 2025 earnings report. The company plans to webcast the conference call on Tuesday, Jan. 27, at 3:30 p.m. Central time. CEO Haviv Ilan and CFO Rafael Lizardi will be leading the discussion. Ti

Traders are focused on any change in order patterns and inventory levels—that is, whether customers are still clearing out old chips or have returned to steady buying, especially in industrial and automotive sectors. Reuters

The sector scene is active as well. Taiwan Semiconductor is set to unveil a hefty jump in quarterly profits, fueled by sustained AI infrastructure demand. This could give chip sentiment another boost. Reuters

This week’s calendar features U.S. inflation figures alongside a busy stretch of corporate earnings. Both have the potential to shake bond yields sharply — a key factor for long-duration tech stocks, including under-the-radar players like TI. Reuters

There’s a clear risk here: should rates surge or industrial demand stay weak, TI’s cautious streak could persist. The company has flagged tariff-related uncertainty and a slower rebound in analog sales before, and investors are still jittery about hearing that again. Reuters

As the week winds down, eyes remain on TXN to see if it can hold its ground alongside the broader chip sector. Attention will then turn to Jan. 27, when management’s guidance and remarks are expected to chart the stock’s next move.

Stock Market Today

  • Teacher Retirement System of Texas Boosts Pfizer Holdings by 32.3% in Q3
    February 2, 2026, 10:44 AM EST. Teacher Retirement System of Texas increased its Pfizer Inc. (NYSE:PFE) shares by 32.3%, acquiring 675,419 shares to hold 2.76 million shares worth $70.43 million at quarter-end. Other investors like Brighton Jones LLC and Revolve Wealth Partners also raised stakes. Pfizer reported quarterly earnings of $0.87 per share, surpassing estimates by $0.08, with net margin at 15.65%. Revenue stood at $16.65 billion, slightly below expectations. The company projects 2025 earnings per share between $3.00 and $3.15. Pfizer's stock recently traded near a 52-week high of $27.69 with a market cap of $148.34 billion. Institutional investors hold 68.36% of shares, reflecting strong confidence amid mixed earnings and moderate revenue performance.
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows
Previous Story

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop
Next Story

Mesoblast (MESO) stock drops 11% as traders digest insider buy and Ryoncil sales backdrop

Go toTop